ORGANIZATION

• Cancel or Postpone FY2025 Revision, or Scrap Off-Year Scheme: New JPA Chief
  July 19, 2024

• FIRM Hails Guidance on Conditional Approval of Regenerative Medicines
  July 17, 2024

• EFPIA Japan Names Yoshiaki Aono as Director General
  July 11, 2024

• Labor Union Group Urges Abolishment of Off-Year Price Revisions
  June 27, 2024

• Japan Digital Health Alliance Keen to Boost Ties with Overseas Organizations
  June 21, 2024

• JGA to Establish Study Group on Generic Industry Realignment
  June 21, 2024

• Majority of Candidates for G1 Withdrawal Scheme Not Able to Exit Market: FPMAJ Survey
  June 17, 2024

• FPMAJ Hails 2024 Reform, but Frets No Mention of Scrapping Off-Year Cuts in Honebuto Draft
  June 17, 2024

• EFPIA Japan Issues New Proposal on HTA, Calls for Transparency
  June 10, 2024

• 135 Meds Still in Lag/Loss State in Japan, JPMA Task Force Revving Up Fight
  June 5, 2024

• JPMA Pushing Industry-Academia Consortia in Non-Competitive Drug Discovery Fields
  June 5, 2024

• JPMA, PhRMA, EFPIA to Jointly Survey Views on 2024 Drug Pricing Reform
  May 24, 2024

• New Task Force Discussing Steps to Stem Further Increase in Drug Lag/Loss: JPMA
  April 30, 2024

• JPMA Eager to Work with Regulators to Improve Guidance on Orphan Meds, PI Trials
  April 30, 2024

• Policymakers Prod for Industry’s Concrete Actions Toward Eliminating Drug Loss
  April 24, 2024

• Govt Should Buy Up Domestic Antibiotic APIs, Cost 5-8 Times Higher: Industry Official
  April 24, 2024

• JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
  April 19, 2024

• Doctors’ Lobby Objects MOF Proposal for CEA Use in Reimbursement Decisions
  April 18, 2024

• Only 3 Prefectures Log “Below 80%” Generic Rate in November: Kyokai Kenpo
  April 10, 2024

• JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
  April 9, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• …
• Next ›
• 最終 »